| Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies U Nayar, O Cohen, C Kapstad, MS Cuoco, AG Waks, SA Wander, ... Nature genetics 51 (2), 207-216, 2019 | 224 | 2019 |
| The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Hormone Receptor Positive Metastatic Breast Cancer Cancer Discovery, 2020 | 219 | 2020 |
| Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer P Mao, O Cohen, KJ Kowalski, JG Kusiel, JE Buendia-Buendia, ... Clinical Cancer Research 26 (22), 5974-5989, 2020 | 112 | 2020 |
| Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies U Nayar, P Lu, RL Goldstein, J Vider, G Ballon, A Rodina, T Taldone, ... Blood, The Journal of the American Society of Hematology 122 (16), 2837-2847, 2013 | 77 | 2013 |
| Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases NS Persky, D Hernandez, M Do Carmo, L Brenan, O Cohen, S Kitajima, ... Nature Structural & Molecular Biology 27 (1), 92-104, 2020 | 38 | 2020 |
| Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors … SA Wander, O Cohen, GN Johnson, D Kim, F Luo, P Mao, U Nayar, ... Journal of Clinical Oncology 36 (15_suppl), 12016-12016, 2018 | 12 | 2018 |
| Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies U Nayar, J Sadek, J Reichel, D Hernandez-Hopkins, G Akar, PJ Barelli, ... The Journal of clinical investigation 127 (6), 2066-2080, 2017 | 9 | 2017 |
| A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression JO Brett, TD Dubash, GN Johnson, A Niemierko, V Mariotti, LSL Kim, J Xi, ... JCO Precision Oncology 7, e2200532, 2023 | 6 | 2023 |
| cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries M Qi, U Nayar, LS Ludwig, N Wagle, E Rheinbay BMC bioinformatics 22 (1), 1-14, 2021 | 4 | 2021 |
| Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+ … SA Wander, O Cohen, X Gong, GN Johnson, J Buendia-Buendia, M Lloyd, ... Cancer Research 80 (4_Supplement), PD2-09-PD2-09, 2020 | 4 | 2020 |
| Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models SA Wander, P Mao, MR Lloyd, GN Johnson, K Kowalski, U Nayar, ... Cancer Research 81 (4_Supplement), PD7-08-PD7-08, 2021 | 3 | 2021 |
| Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole … O Cohen, J Buendia-Buendia, S Wander, U Nayar, P Mao, A Waks, D Kim, ... Cancer Research 79 (4_Supplement), PD9-02-PD9-02, 2019 | 2 | 2019 |
| Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole … O Cohen, J Buendia-Buendia, S Wander, U Nayar, P Mao, A Waks, D Kim, ... Cancer Research 79 (4_Supplement), PD9-02-PD9-02, 2019 | 2 | 2019 |
| Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies U Nayar, O Cohen, C Kapstad, A Waks, SA Wander, C Painter, ... Cancer Research 78 (13_Supplement), 4952-4952, 2018 | 2 | 2018 |
| Abstract PS5-10: Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive … SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ... Cancer Research 81 (4_Supplement), PS5-10-PS5-10, 2021 | 1 | 2021 |
| Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr plus) metastatic breast … SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ... CANCER RESEARCH 81 (4), 2021 | 1 | 2021 |
| Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma U Nayar, P Lu, J Vider, L Cerchietti, G Chiosis, L Wang, R Blasberg, ... Infectious Agents and Cancer 5, 1-2, 2010 | 1 | 2010 |
| Novel nucleoside analogs and use thereof in therapeutic treatment E Cesarman, U Nayar, JD Warren, J Sadek US Patent App. 18/525,031, 2024 | | 2024 |
| Systematic functional and phenotypic characterization of HER2 missense mutants and their impact in ER+ metastatic breast cancer NV Guevara, Z Zhu, E Jain, J Kavran, S Arslan, N Wagle, U Nayar Cancer Research 83 (7_Supplement), 3877-3877, 2023 | | 2023 |
| Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer U Nayar, F Piccioni, X Yang, D Root, JT Neal, LD Eli, I Diala, AS Lalani, ... Cancer Research 80 (16_Supplement), 1914-1914, 2020 | | 2020 |
Nikhil WagleDana-Farber Cancer Institute, Harvard Medical School / Broad Institute of MIT and HarvardVerified email at dfci.harvard.edu
